Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
3D & 4D Printing Methods for Pharmaceutical Manufacturing and Personalised Drug Delivery [[electronic resource] ] : Opportunities and Challenges / / edited by Dimitrios Lamprou
| 3D & 4D Printing Methods for Pharmaceutical Manufacturing and Personalised Drug Delivery [[electronic resource] ] : Opportunities and Challenges / / edited by Dimitrios Lamprou |
| Autore | Lamprou Dimitrios |
| Edizione | [1st ed. 2023.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Springer, , 2023 |
| Descrizione fisica | 1 online resource (329 pages) |
| Disciplina | 615.19 |
| Collana | AAPS Introductions in the Pharmaceutical Sciences |
| Soggetto topico |
Pharmaceutical chemistry
Drugs—Design Pharmacology Pharmaceutics Structure-Based Drug Design |
| ISBN | 3-031-34119-8 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | 3D and 4D printing in digital healthcare -- 3D Printing for Novel Dosage Form Design -- 3D Printing and regulatory considerations -- Printability of Pharmaceutical Polymers: Issues & Solutions -- Quality by Design (QbD) approach for individualized products based on additive manufacturing,- Material Properties and Selections for Additive Manufacturing (AM) -- Preformulation of 3D printable pharmaceutical dosage forms -- Vat photopolymerization Methods for Drug Delivery Applications -- Extrusion-based 3D printing methods for oral solid dosage forms -- Binder Jetting 3D Printing in Pharmaceutical Manufacturing -- Powder bed fusion 3D printing in drug delivery -- Bioprinting in Personalised Medications -- Shape memory materials and 4D printing in pharmaceutics -- Characterisation methods of final printed products. |
| Record Nr. | UNINA-9910736994803321 |
Lamprou Dimitrios
|
||
| Cham : , : Springer International Publishing : , : Imprint : Springer, , 2023 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
3D Printing [[electronic resource] ] : Emerging Technologies and Functionality of Polymeric Excipients in Drug Product Development / / edited by Michael A. Repka, Nigel Langley
| 3D Printing [[electronic resource] ] : Emerging Technologies and Functionality of Polymeric Excipients in Drug Product Development / / edited by Michael A. Repka, Nigel Langley |
| Autore | Repka Michael A |
| Edizione | [1st ed. 2024.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Springer, , 2024 |
| Descrizione fisica | 1 online resource (287 pages) |
| Disciplina | 621.988 |
| Altri autori (Persone) | LangleyNigel |
| Collana | AAPS Advances in the Pharmaceutical Sciences Series |
| Soggetto topico |
Pharmaceutical chemistry
Pharmacology Biotechnology Biology - Technique Pharmaceutics Biological Techniques |
| ISBN | 3-031-46015-4 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Overview of Pharmaceutical 3D Printing Technologies -- Clinical Benefit of 3D Printed Products -- Characterization or Quality Control of 3D Printed Products -- Polymers for HME based 3D Printing -- Cellulosic Polymers -- API and Polymer Selection Formulation and Process Variables -- Fused Deposition Modeling 3D Printing.-Semi-solid Extrusion Printing and 3D -- Future Trends Including Novel Polymeric Excipients Designed for Purpose Bioprinting. |
| Record Nr. | UNINA-9910767526003321 |
|
Repka Michael A
|
||
| Cham : , : Springer International Publishing : , : Imprint : Springer, , 2024 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Acetylsalicylic Acid / / Karsten Schrör
| Acetylsalicylic Acid / / Karsten Schrör |
| Autore | Schrör Karsten |
| Edizione | [Third edition.] |
| Pubbl/distr/stampa | Berlin : , : De Gruyter, , 2022 |
| Descrizione fisica | 1 online resource (vii, 623 pages) |
| Disciplina | 615.19 |
| Soggetto topico | Pharmaceutical chemistry |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910629590103321 |
|
Schrör Karsten
|
||
| Berlin : , : De Gruyter, , 2022 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
ACS bio & med chem Au
| ACS bio & med chem Au |
| Pubbl/distr/stampa | Columbus, OH : , : American Chemical Society, , [2021]- |
| Descrizione fisica | 1 online resource |
| Disciplina | 547.7 |
| Soggetto topico |
Biochemistry
Pharmaceutical chemistry Chemistry, Pharmaceutical |
| Soggetto genere / forma |
Periodical
Periodicals. |
| ISSN | 2694-2437 |
| Formato | Materiale a stampa |
| Livello bibliografico | Periodico |
| Lingua di pubblicazione | eng |
| Altri titoli varianti | ACS bio and med chem Au |
| Record Nr. | UNISA-996456638703316 |
| Columbus, OH : , : American Chemical Society, , [2021]- | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. di Salerno | ||
| ||
ACS bio & med chem Au
| ACS bio & med chem Au |
| Pubbl/distr/stampa | Columbus, OH : , : American Chemical Society, , [2021]- |
| Descrizione fisica | 1 online resource |
| Disciplina | 547.7 |
| Soggetto topico |
Biochemistry
Pharmaceutical chemistry Chemistry, Pharmaceutical |
| Soggetto genere / forma |
Periodical
Periodicals. |
| ISSN | 2694-2437 |
| Formato | Materiale a stampa |
| Livello bibliografico | Periodico |
| Lingua di pubblicazione | eng |
| Altri titoli varianti | ACS bio and med chem Au |
| Record Nr. | UNINA-9910514190303321 |
| Columbus, OH : , : American Chemical Society, , [2021]- | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
ACS medicinal chemistry letters
| ACS medicinal chemistry letters |
| Pubbl/distr/stampa | Washington, D.C., : American Chemical Society |
| Descrizione fisica | 1 online resource |
| Disciplina | 615 |
| Soggetto topico |
Pharmaceutical chemistry
Chemistry, Pharmaceutical Medizin Chemie |
| Soggetto genere / forma |
Periodical
Fulltext Internet Resources. Periodicals. Zeitschrift Online-Publikation |
| Soggetto non controllato | Pharmacy, Therapeutics, & Pharmacology |
| ISSN | 1948-5875 |
| Formato | Materiale a stampa |
| Livello bibliografico | Periodico |
| Lingua di pubblicazione | eng |
| Altri titoli varianti |
American Chemical Society medicinal chemistry letters
Medicinal chemistry letters |
| Record Nr. | UNINA-9910139947603321 |
| Washington, D.C., : American Chemical Society | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Additive Manufacturing in Pharmaceuticals [[electronic resource] /] / edited by Subham Banerjee
| Additive Manufacturing in Pharmaceuticals [[electronic resource] /] / edited by Subham Banerjee |
| Autore | Banerjee Subham |
| Edizione | [1st ed. 2023.] |
| Pubbl/distr/stampa | Singapore : , : Springer Nature Singapore : , : Imprint : Springer, , 2023 |
| Descrizione fisica | 1 online resource (378 pages) |
| Disciplina | 615.6 |
| Soggetto topico |
Pharmaceutical chemistry
Drug delivery systems Pharmacology Pharmaceutics Drug Delivery |
| ISBN | 981-9924-04-9 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | 1. History and Present Scenario of Additive Manufacturing in Pharmaceuticals -- 2. Fused deposition modeling (FDM) of Pharmaceuticals -- 3. Stereolithography (SLA) in Pharmaceuticals -- 4. Selective Laser Sintering (SLS) In Pharmaceuticals -- 5. Semi-solid Extrusion (SSE) in Pharmaceuticals -- 6. Inkjet and Binder Jet Printing in Pharmaceuticals -- 7. 4D printing: The next dimension of healthcare in cancer research -- 8. 4D Printing in Pharmaceuticals -- 9. Bioprinting in Pharmaceuticals -- 10. Regulatory Perspective of Additive Manufacturing in the Field of Pharmaceuticals -- 11. Machine Learning in Additive Manufacturing of Pharmaceuticals. . |
| Record Nr. | UNINA-9910746101003321 |
|
Banerjee Subham
|
||
| Singapore : , : Springer Nature Singapore : , : Imprint : Springer, , 2023 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
ADME Processes in Pharmaceutical Sciences [[electronic resource] ] : Dosage, Design, and Pharmacotherapy / / edited by Alan Talevi, Pablo A. Quiroga
| ADME Processes in Pharmaceutical Sciences [[electronic resource] ] : Dosage, Design, and Pharmacotherapy / / edited by Alan Talevi, Pablo A. Quiroga |
| Autore | Talevi Alan |
| Edizione | [2nd ed. 2024.] |
| Pubbl/distr/stampa | Cham : , : Springer Nature Switzerland : , : Imprint : Springer, , 2024 |
| Descrizione fisica | 1 online resource (489 pages) |
| Disciplina | 615.19 |
| Altri autori (Persone) | QuirogaPablo A |
| Soggetto topico |
Pharmaceutical chemistry
Pharmacology Toxicology Pharmacy Drugs - Design Pharmaceutics Structure-Based Drug Design |
| ISBN | 3-031-50419-4 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Part 1: The basics of ADME processes -- Chapter 1-Introduction. Biopharmaceutics and Pharmacokinetics -- Chapter 2-Drug release -- Chapter 3-Drug Absorption -- Chapter 4-Drug Distribution -- Chapter 5-Drug Metabolism -- Chapter 6-Drug Excretion -- Chapter 7-Drug Delivery Routes -- Chapter 8-Compartmental Pharmacokinetic Models -- Chapter 9-Regulatory Requirements and Applications of Physiologically Based Pharmacokinetic Models -- Chapter 10-Drug Drug and Food Drug Interactions of Pharmacokinetic Nature -- Part 2: Specialized topics -- Chapter 11-Nanocarriers: Delivery Routes -- Chapter 12-Advanced Techniques for Quality Assessment of Nanocarriers -- Chapter 13-Nanomedicines Obtained by Nanoprinting -- Chapter 14-Absorption, Distribution, Metabolism and Excretion of Biopharmaceutical Drug Products -- Chapter 15-In silico and in vitro ADME predictions -- Chapter 16-Relationship Between Pharmacokinetics and Pharmacogenomics and Its Impact on Drug Choice and Dose Regimens -- Chapter 17-The Relationship Between Pharmacogenomics and Pharmacokinetics and Its Impact on Drug Choice and Dosing Regimens in Pediatrics -- Chapter 18-Bioavailability and Bioequivalence studies -- Chapter 19-Drug transporters – Physiological role and Their Impact on Pharmacotherapy -- Chapter 20-Blood Flow Distribution and Membrane Transporters As Determinant Factors Of Tissue Drug Concentration. |
| Record Nr. | UNINA-9910847085703321 |
|
Talevi Alan
|
||
| Cham : , : Springer Nature Switzerland : , : Imprint : Springer, , 2024 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
ADME-enabling technologies for drug design and development [[electronic resource] /] / edited by Donglu Zhang, Sekhar Surapaneni
| ADME-enabling technologies for drug design and development [[electronic resource] /] / edited by Donglu Zhang, Sekhar Surapaneni |
| Pubbl/distr/stampa | Hoboken, N.J., : Wiley, c2012 |
| Descrizione fisica | 1 online resource (623 p.) |
| Disciplina | 615.1/9 |
| Altri autori (Persone) |
ZhangDonglu
SurapaneniSekhar |
| Soggetto topico |
Drugs - Design
Drug development Drugs - Metabolism Pharmaceutical chemistry Pharmacokinetics Pharmaceutical technology |
| ISBN |
1-280-59257-5
9786613622402 1-118-18076-3 1-118-18077-1 1-118-18074-7 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
ADME-Enabling Technologies in Drug Design and Development; CONTENTS; FOREWORD; PREFACE; CONTRIBUTORS; PART A: ADME: OVERVIEW AND CURRENT TOPICS; 1: REGULATORY DRUG DISPOSITION AND NDA PACKAGE INCLUDING MIST; 1.1 INTRODUCTION; 1.2 NONCLINICAL OVERVIEW; 1.3 PK; 1.4 ABSORPTION; 1.5 DISTRIBUTION; 1.5.1 Plasma Protein Binding; 1.5.2 Tissue Distribution; 1.5.3 Lacteal and Placental Distribution Studies; 1.6 METABOLISM; 1.6.1 In vitro Metabolism Studies; 1.6.2 Drug-Drug Interaction Studies; 1.6.3 In vivo Metabolism (ADME) Studies; 1.7 EXCRETION; 1.8 IMPACT OF METABOLISM INFORMATION ON LABELING
1.9 CONCLUSIONSREFERENCES; 2: OPTIMAL ADME PROPERTIES FOR CLINICAL CANDIDATE AND INVESTIGATIONAL NEW DRUG (IND) PACKAGE; 2.1 INTRODUCTION; 2.2 NCE AND INVESTIGATIONAL NEW DRUG (IND) PACKAGE; 2.3 ADME OPTIMIZATION; 2.3.1 Absorption; 2.3.2 Metabolism; 2.3.3 PK; 2.4 ADME OPTIMIZATION FOR CNS DRUGS; 2.5 SUMMARY; REFERENCES; 3: DRUG TRANSPORTERS IN DRUG INTERACTIONS AND DISPOSITION; 3.1 INTRODUCTION; 3.2 ABC TRANSPORTERS; 3.2.1 Pgp (MDR1, ABCB1); 3.2.2 BCRP (ABCG2); 3.2.3 MRP2 (ABCC2); 3.3 SLC TRANSPORTERS; 3.3.1 OCT1 (SLC22A1) and OCT2 (SLC22A2); 3.3.2 MATE1 (SLC47A1) and MATE2K (SLC47A2) 3.3.3 OAT1 (SLC22A6) and OAT3 (SLC22A8)3.3.4 OATP1B1 (SLCO1B1, SLC21A6), OATP1B3 (SLCO1B3, SLC21A8), and OATP2B1 (SLCO2B1, SLC21A9); 3.4 IN VITRO ASSAYS IN DRUG DEVELOPMENT; 3.4.1 Considerations for Assessing Candidate Drugs as Inhibitors; 3.4.2 Considerations for Assessing Candidate Drugs as Substrates; 3.4.3 Assay Systems; 3.5 CONCLUSIONS AND PERSPECTIVES; REFERENCES; 4: PHARMACOLOGICAL AND TOXICOLOGICAL ACTIVITY OF DRUG METABOLITES; 4.1 INTRODUCTION; 4.2 ASSESSMENT OF POTENTIAL FOR ACTIVE METABOLITES; 4.2.1 Detection of Active Metabolites during Drug Discovery 4.2.2 Methods for Assessing and Evaluating the Biological Activity of Metabolite Mixtures4.2.3 Methods for Generation of Metabolites; 4.3 ASSESSMENT OF THE POTENTIAL TOXICOLOGY OF METABOLITES; 4.3.1 Methods to Study the Formation of Reactive Metabolites; 4.3.2 Reactive Metabolite Studies: In vitro; 4.3.3 Reactive Metabolite Studies: In vivo; 4.3.4 Reactive Metabolite Data Interpretation; 4.3.5 Metabolite Contribution to Off-Target Toxicities; 4.4 SAFETY TESTING OF DRUG METABOLITES; 4.5 SUMMARY; REFERENCES 5: IMPROVING THE PHARMACEUTICAL PROPERTIES OF BIOLOGICS IN DRUG DISCOVERY: UNIQUE CHALLENGES AND ENABLING SOLUTIONS5.1 INTRODUCTION; 5.2 PHARMACOKINETICS; 5.3 METABOLISM AND DISPOSITION; 5.4 IMMUNOGENICITY; 5.5 TOXICITY AND PRECLINICAL ASSESSMENT; 5.6 COMPARABILITY; 5.7 CONCLUSIONS; REFERENCES; 6: CLINICAL DOSE ESTIMATION USING PHARMACOKINETIC/PHARMACODYNAMIC MODELING AND SIMULATION; 6.1 INTRODUCTION; 6.2 BIOMARKERS IN PK AND PD; 6.2.1 PK; 6.2.2 PD; 6.2.3 Biomarkers; 6.3 MODEL-BASED CLINICAL DRUG DEVELOPMENT; 6.3.1 Modeling; 6.3.2 Simulation; 6.3.3 Population Modeling 6.3.4 Quantitative Pharmacology (QP) and Pharmacometrics |
| Record Nr. | UNINA-9910141254203321 |
| Hoboken, N.J., : Wiley, c2012 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
ADME-enabling technologies for drug design and development [[electronic resource] /] / edited by Donglu Zhang, Sekhar Surapaneni
| ADME-enabling technologies for drug design and development [[electronic resource] /] / edited by Donglu Zhang, Sekhar Surapaneni |
| Pubbl/distr/stampa | Hoboken, N.J., : Wiley, c2012 |
| Descrizione fisica | 1 online resource (623 p.) |
| Disciplina | 615.1/9 |
| Altri autori (Persone) |
ZhangDonglu
SurapaneniSekhar |
| Soggetto topico |
Drugs - Design
Drug development Drugs - Metabolism Pharmaceutical chemistry Pharmacokinetics Pharmaceutical technology |
| ISBN |
1-280-59257-5
9786613622402 1-118-18076-3 1-118-18077-1 1-118-18074-7 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
ADME-Enabling Technologies in Drug Design and Development; CONTENTS; FOREWORD; PREFACE; CONTRIBUTORS; PART A: ADME: OVERVIEW AND CURRENT TOPICS; 1: REGULATORY DRUG DISPOSITION AND NDA PACKAGE INCLUDING MIST; 1.1 INTRODUCTION; 1.2 NONCLINICAL OVERVIEW; 1.3 PK; 1.4 ABSORPTION; 1.5 DISTRIBUTION; 1.5.1 Plasma Protein Binding; 1.5.2 Tissue Distribution; 1.5.3 Lacteal and Placental Distribution Studies; 1.6 METABOLISM; 1.6.1 In vitro Metabolism Studies; 1.6.2 Drug-Drug Interaction Studies; 1.6.3 In vivo Metabolism (ADME) Studies; 1.7 EXCRETION; 1.8 IMPACT OF METABOLISM INFORMATION ON LABELING
1.9 CONCLUSIONSREFERENCES; 2: OPTIMAL ADME PROPERTIES FOR CLINICAL CANDIDATE AND INVESTIGATIONAL NEW DRUG (IND) PACKAGE; 2.1 INTRODUCTION; 2.2 NCE AND INVESTIGATIONAL NEW DRUG (IND) PACKAGE; 2.3 ADME OPTIMIZATION; 2.3.1 Absorption; 2.3.2 Metabolism; 2.3.3 PK; 2.4 ADME OPTIMIZATION FOR CNS DRUGS; 2.5 SUMMARY; REFERENCES; 3: DRUG TRANSPORTERS IN DRUG INTERACTIONS AND DISPOSITION; 3.1 INTRODUCTION; 3.2 ABC TRANSPORTERS; 3.2.1 Pgp (MDR1, ABCB1); 3.2.2 BCRP (ABCG2); 3.2.3 MRP2 (ABCC2); 3.3 SLC TRANSPORTERS; 3.3.1 OCT1 (SLC22A1) and OCT2 (SLC22A2); 3.3.2 MATE1 (SLC47A1) and MATE2K (SLC47A2) 3.3.3 OAT1 (SLC22A6) and OAT3 (SLC22A8)3.3.4 OATP1B1 (SLCO1B1, SLC21A6), OATP1B3 (SLCO1B3, SLC21A8), and OATP2B1 (SLCO2B1, SLC21A9); 3.4 IN VITRO ASSAYS IN DRUG DEVELOPMENT; 3.4.1 Considerations for Assessing Candidate Drugs as Inhibitors; 3.4.2 Considerations for Assessing Candidate Drugs as Substrates; 3.4.3 Assay Systems; 3.5 CONCLUSIONS AND PERSPECTIVES; REFERENCES; 4: PHARMACOLOGICAL AND TOXICOLOGICAL ACTIVITY OF DRUG METABOLITES; 4.1 INTRODUCTION; 4.2 ASSESSMENT OF POTENTIAL FOR ACTIVE METABOLITES; 4.2.1 Detection of Active Metabolites during Drug Discovery 4.2.2 Methods for Assessing and Evaluating the Biological Activity of Metabolite Mixtures4.2.3 Methods for Generation of Metabolites; 4.3 ASSESSMENT OF THE POTENTIAL TOXICOLOGY OF METABOLITES; 4.3.1 Methods to Study the Formation of Reactive Metabolites; 4.3.2 Reactive Metabolite Studies: In vitro; 4.3.3 Reactive Metabolite Studies: In vivo; 4.3.4 Reactive Metabolite Data Interpretation; 4.3.5 Metabolite Contribution to Off-Target Toxicities; 4.4 SAFETY TESTING OF DRUG METABOLITES; 4.5 SUMMARY; REFERENCES 5: IMPROVING THE PHARMACEUTICAL PROPERTIES OF BIOLOGICS IN DRUG DISCOVERY: UNIQUE CHALLENGES AND ENABLING SOLUTIONS5.1 INTRODUCTION; 5.2 PHARMACOKINETICS; 5.3 METABOLISM AND DISPOSITION; 5.4 IMMUNOGENICITY; 5.5 TOXICITY AND PRECLINICAL ASSESSMENT; 5.6 COMPARABILITY; 5.7 CONCLUSIONS; REFERENCES; 6: CLINICAL DOSE ESTIMATION USING PHARMACOKINETIC/PHARMACODYNAMIC MODELING AND SIMULATION; 6.1 INTRODUCTION; 6.2 BIOMARKERS IN PK AND PD; 6.2.1 PK; 6.2.2 PD; 6.2.3 Biomarkers; 6.3 MODEL-BASED CLINICAL DRUG DEVELOPMENT; 6.3.1 Modeling; 6.3.2 Simulation; 6.3.3 Population Modeling 6.3.4 Quantitative Pharmacology (QP) and Pharmacometrics |
| Record Nr. | UNINA-9910816078003321 |
| Hoboken, N.J., : Wiley, c2012 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Soggetto topico
-
Pharmaceutical chemistry
(554)
- Drugs - Design (92)
- Pharmaceutics (73)
- Pharmacology (66)
- Chemistry, Pharmaceutical (55)